urabrelimab (SRF231) / Coherus Oncology - LARVOL DELTA

CD47-blockade induces programmed necroptosis and complements the effects of BCL-2 inhibition in lymphoid malignancies (ASH 2025) - "Methodology: The fully humanized anti-CD47 monoclonal antibodies, SRF231, magrolimab, as well as themouse monoclonal anti-CD47 antibody, B6H12, were evaluated in this study. Our study unravels a novel, critical non-canonical cell death mechanism of targeting CD47 vianecroptosis. We also demonstrate the complementary and distinct cell death mechanisms of SRF231-induced necroptosis and venetoclax-induced apoptosis, a combination worthy of further study in theclinic specifically against BCL-2-dependent lymphoid malignancies."

Acute Lymphocytic Leukemia • B Cell Lymphoma • Burkitt Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ANXA5

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax (ASH 2018) - P1; "In vivo, SRF231 in combination with VEN led to complete and durable tumor regression in a xenograft model. SRF231 is currently being evaluated across multiple tumor types in a Phase 1 clinical trial (NCT03512340)."

IO biomarker • Biosimilar • Chronic Lymphocytic Leukemia • Gene Therapies • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

SRF231, a fully human high-affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the Fc receptor (FcR), CD32a (SITC 2019) - P1; "SRF231 is a high affinity, CD47-targeting antibody that delivers an activating signal to myeloid cells via CD32a and displays favorable preclinical characteristics regarding its RO/tumor exposure/efficacy relationship. SRF231 is currently being evaluated in a Phase 1 clinical trial [NCT03512340] in advanced solid tumors and lymphomas. Understanding these PK/PD/tumor exposure/efficacy relationships, as well as the role of target vs FcR affinity, offers guidance on the development of CD47 antagonists for patients with cancer."

Preclinical

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas (ASH 2018) - P1; "Finally, we observed that in our HSTL PDX model, depletion of macrophages with clodronate completely abrogated the antitumor efficacy of SRF231 while depletion of neutrophils with anti-Ly6G Ab had no effect, highlighting macrophages as the essential effectors of phagocytosis in this context. In summary, monoclonal antibodies that disrupt CD47-SIRPα have striking in vitro and in vivo preclinical efficacy but require interactions with human FcγR on macrophages to maximize efficacy."

Biosimilar • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

[VIRTUAL] Results of a first-in-human phase I study of SRF231, a fully human, high‑affinity anti‑CD47 antibody. (ASCO 2020) - P1 | "Preliminary data from a Phase 1 study of SRF231, an anti-CD47 antibody, demonstrate that SRF231 may be administered safely and doses of 4.0 mg/kg weekly maintain > 90% receptor occupancy throughout the dosing period. Updated safety data, clinical outcomes, and PK/pharmacodynamic data will be presented. Research Funding: Surface Oncology, Inc."

P1 data • Fatigue • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology • Thrombocytopenia

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers (clinicaltrials.gov) - P1; N=148; Completed; Sponsor: Surface Oncology; Active, not recruiting ➔ Completed

Clinical • Trial completion • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

[VIRTUAL] Serological Interference in Patients Receiving SRF231 Anti-CD47 Immunotherapy (AABB 2020) - "Despite the observation that SRF231 does not directly agglutinate RBCs in vitro, we show SRF231 anti-CD47 therapy interferes with routine pre-transfusion testing. SRF231 did not cause spontaneous agglutination or interfere with ABO reverse typing as observed with Hu5F9-G4 (Velliquette et al. Transfusion 2019 Feb;59(2):730-737)."

Clinical • Hematological Malignancies • Oncology

[VIRTUAL] SRF231, a fully human CD47 antibody, potentiates the effects of opsonizing antibodies and cytotoxic chemotherapies in preclinical cancer models (AACR-II 2020) - "Enhanced ADCP was observed with SRF231 in combination with opsonizing antibodies elotuzumab (anti-SLAMF7) and daratumumab (anti-CD38)...Cisplatin monotherapy induced modest H1975 anti-tumor activity; however, combination with SRF231 potentiated the effect of cisplatin in this model. Additionally, combination of SRF231 with docetaxel resulted in a 45% CR rate and a significant delay in H1975 tumor regrowth, as compared to a 100% regrowth rate with docetaxel monotherapy.In summary, SRF231 demonstrated significant anti-tumor activity in combination with the anti-SLAMF7 opsonizing antibody, elotuzumab, in preclinical MM xenograft models. Moreover, SRF231 potentiated the effects of taxane and platinum-based standard of care chemotherapies in preclinical NSCLC xenograft models. These results offer further guidance on the clinical development of anti-CD47 modalities in cancer treatment."

IO Biomarker • Preclinical • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Thoracic Cancer • CD38 • EGFR • FCGR2A

[VIRTUAL] The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer (AACR-II 2020) - "SRF231 potentiated doxorubicin- or oxaliplatin-mediated cell death in Jurkat cells in Annexin V assays. Anti-CD47 directed therapy with SRF231, a fully human antibody, demonstrated the ability to significantly increase the anti-tumor activity of standard chemotherapies in xenograft and platinum-resistant PDX models of ovarian cancer. Further exploration of combining anti-CD47 and platinum regimens in ovarian cancer is warranted."

Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Surface Oncology to present preclinical data for multiple product programs at the American Association for Cancer Research Annual Meeting (GlobeNewswire) - "Surface Oncology...announced five scientific posters sharing updated preclinical data at the American Association for Cancer Research (AACR) 2020 Annual Meeting, to be held virtually on June 22-24. The posters include preclinical data from Surface Oncology’s two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27). Three additional posters containing preclinical data from SRF813 (targeting CD112R) and SRF231 (targeting CD47) will also be presented."

Preclinical • Hematological Malignancies • Oncology • Ovarian Cancer • Renal Cell Carcinoma

Surface Oncology to present preclinical data for multiple product programs at the American Association for Cancer Research Annual Meeting (GlobeNewswire, Surface Oncology, Inc.) - "Surface Oncology...today announced five scientific posters sharing updated preclinical data at the American Association for Cancer Research (AACR) 2020 Annual Meeting, to be held virtually on June 22-24....Title: The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer, Lead Author: Joyce Fu Liu, M.D., Date and Time: Monday, June 22nd, 9:00 a.m. EDT."

Genito-urinary Cancer • Hematological Malignancies • Oncology • Renal Cell Carcinoma • Solid Tumor

Surface Oncology to present at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire) - "Surface Oncology…announced that data from the Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31."

P1 data • Oncology

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a. (PubMed, J Immunother Cancer) - "SRF231 elicits antitumor activity via apoptosis and phagocytosis involving macrophage engagement in a manner dependent on the FcγR, CD32a."

Journal • Hematological Disorders • Hematological Malignancies • Oncology • CCL3 • FCGR2A

Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers (clinicaltrials.gov) - P1; N=148; Active, not recruiting; Sponsor: Surface Oncology; Recruiting ➔ Active, not recruiting

Enrollment closed

Surface Oncology presents updates at the Society for Immunotherapy of Cancer’s Annual Meeting (GlobeNewswire) - "The presentations will include posters highlighting preclinical data from three programs in the Company’s portfolio, SRF388 (targeting IL-27), SRF617 (targeting CD39) and SRF231 (targeting CD47)....'Each therapeutic candidate at Surface provides a compelling and differentiated biological rationale as an anti-tumor agent, with SRF617 and SRF388 IND filings anticipated in the fourth quarter of 2019'"

IND • Preclinical

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019 (GlobeNewswire, Surface Oncology, Inc.) - Presented preclinical data further supporting the anti-tumor mechanisms for SRF617 (targeting CD39; currently in IND-enabling studies) and NZV930 (targeting CD73; currently in phase 1) at the Brisbane Immunotherapy 2019 Conference in May. The ongoing phase 1b study of NZV930 (CD73), licensed to Novartis, is continuing to enroll and is evaluating combinations of NZV930 with PDR001 (anti PD-1), NIR178 (A2aR inhibitor), as well as a triplet combination of all three therapies. Submitted multiple abstracts for presentation at the Society for the Immunotherapy of Cancer (SITC) Conference discussing data from the SRF617, SRF388 and SRF231 programs. Continued preparation to file Investigational New Drug applications for both SRF617 and SRF388 in Q4 of 2019. These filings will be staggered, with the IND for SRF617 to be filed first.

Commercial • Preclinical • Regulatory • Tumor microenvironment

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2018 (GlobeNewswire, Surface Oncology, Inc.) - "Selected Anticipated 2019 Corporate Milestones: Additional findings and learnings related to the deprioritization of SRF231 in H2 2019."

Clinical